Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Inclusion Criteria

• •Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
• •Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to allow for assessment of drug activity.
• •Evidence of CD123 expression from a local laboratory.
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2